Axitinib versus sorafenib as a second-line therapy in Asian patients with metastatic renal cell carcinoma: results from a randomized registrational study

Axitinib versus sorafenib as a second-line therapy in Asian patients with metastatic renal cell carcinoma: results from a randomized registrational study

Shukui Qin,1 Feng Bi,2 Jie Jin,3 Ying Cheng,4 Jun Guo,5 Xiubao Ren,6 Yiran Huang,7 Jamal Tarazi,8 Jie Tang,9 Connie Chen,9 Sinil Kim,8 Dingwei Ye10 1Department of Medical Oncology, PLA Cancer Center, Nanjing Bayi Hospital, Nanjing, Jiangsu, People’s Republic of China; 2Department of Medic...

Full description

Bibliographic Details
Main Authors: Qin S, Bi F, Jin J, Cheng Y, Guo J, Ren X, Huang Y, Tarazi J, Tang J, Chen C, Kim S, Ye D
Format: Article
Language:English
Published: Dove Medical Press 2015-06-01
Series:OncoTargets and Therapy
Online Access:http://www.dovepress.com/axitinib-versus-sorafenib-as-a-second-line-therapy-in-asian-patients-w-peer-reviewed-article-OTT

Internet

http://www.dovepress.com/axitinib-versus-sorafenib-as-a-second-line-therapy-in-asian-patients-w-peer-reviewed-article-OTT

Similar Items